InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,296.40
(
-0.01%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
73.74
(
-0.20%
)
Bitcoin
63,339.41
(
-0.44%
)
Post# of 1367
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

midastouch017

Send PM Follow Ignore
Followers 144
Posts 27707
Boards Moderated 3
Alias Born 02/07/2004

midastouch017

Re: None

Friday, 12/30/2016 9:26:02 AM

Friday, December 30, 2016 9:26:02 AM

Post# of 1367
Protalix BioTherapeutics

Protalix BioTherapeutics Inc. (NYSEMKT: PLX) just finished its final patient enrollment for its Phase 2 clinical trial of AIR DNase (PRX-110) for the treatment of cystic fibrosis. Interim results are expected in the first week of January 2017, with the full results from this mid-stage trial coming before the end of the first quarter of 2017.

Protalix shares were last trading at $0.46 apiece. The stock has a consensus price target of $2.40 and a 52-week trading range of $0.26 to $1.04.

http://247wallst.com/healthcare-business/2016/12/30/7-key-fda-decisions-and-catalysts-expected-in-january-and-february/
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up